Biotech2k
Biotech Investor, AI-Driven Drug Discovery
Axsome and Cytokinetics miss the biotech pick list on drug breadth, while Arrowhead gives away too much upside through partnerships. Auvelity is Axsome's only real blockbuster; Cytokinetics has one great drug, two potentially smaller ones and prior omecamtiv trial failures. Arrowhead kept lackluster cholesterol drugs. The strict screen favors good phase 3 to early-commercial assets, best- or first-in-class drugs, more than one drug and a price below intrinsic value. x.comÂ
Pipeline strength and risk drive biotech ranks. #1 Insmed is the best in over a decade; #2 BridgeBio's four drugs could be commercial by end-2027, but debt limits it. #3 Protagonist relies too much on partners; #4 Mirum has near-term risks; #5 Praxis could rise to #3 if two drugs win December/January approval. #6 IDEAYA, #7 Cogent, #8 Immunome, #9 Belite, #10 DFTX and #11 Summit need more proof. #12 Madrigal's thin pipeline and #13 Zenas's non-leading data make them sales into a rally. x.com x.comÂ
Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.comÂ
Healthcare's rotation from laggard to leader is not done, with the sector coming out of multiyear bases. It has been the most consistent sector in midterm election years for over 30 years, winning 80% of the time in the back half, and 22 healthcare companies beat the S&P 500 in 75%+ of midterms from 1994 to 2022. Focus names range from mature AbbVie, Lilly and UnitedHealth to large caps like Vertex and Amgen and riskier mid caps like Hims & Hers and Oscar Health. Start trimming from November. … Show more
